We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
11
Aug 2026
Light therapy may improve alertness and attention/reaction time during simulated night shifts, with the strongest benefits appearing after light exposure. Effects on executive function were smaller and largely limited to treatment, while substantial study heterogeneity and limited real-world evidence warrant caution.
11
Aug 2026
A Western dietary pattern was associated with faster attention decline among older adults carrying the APOE ε4 allele, while no significant cognitive associations emerged for a Prudent dietary pattern. However, the Western diet association lost statistical significance after excluding participants with possible baseline cognitive impairment, making the finding exploratory.
11
Aug 2026
. Early-life stress increased SETD7 and H3K4me1 in the ventral tegmental area of mice, creating an epigenetically primed state that heightened later transcriptional, neuronal, and behavioral responses to stress. Reducing Setd7 during development lowered H3K4me1 and weakened these stress-sensitizing effects, identifying a mechanism that may help explain how early adversity leaves lasting biological effects.
10
Aug 2026
E-scooter riders admitted with moderate-to-severe trauma showed a distinct injury profile, with proportionally more traumatic brain, vascular, and internal organ injuries than motorcyclists and fewer fractures. Rental-scooter data also linked greater reported injury severity with younger age and female sex, while collision rates varied with area-level deprivation.